Alirocumab
Modify Date: 2024-01-14 19:26:09
Alirocumab structure
|
Common Name | Alirocumab | ||
|---|---|---|---|---|
| CAS Number | 1245916-14-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C6472H9996N1736O2032S42 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AlirocumabAlirocumab (REGN 727) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1]. |
| Name | Alirocumab |
|---|---|
| Synonym | More Synonyms |
| Description | Alirocumab (REGN 727) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705. |
| Molecular Formula | C6472H9996N1736O2032S42 |
|---|
| ALIROCUMAB |